Divergent effects of target protein stabilisation versus overproduction on PROTAC activity

This study demonstrates that while stabilizing oncogenic mutations increase target protein levels without altering the minimum steady-state achievable by PROTACs, transcriptional upregulation raises both baseline and post-treatment protein levels, revealing a synthesis-dependent ceiling on degrader efficacy.

The Gist

The Big Picture: The "Trash Can" Problem

Imagine your body is a bustling city, and your cells are the buildings. Inside these buildings, there are thousands of workers (proteins) doing specific jobs. Sometimes, a worker gets "glitched" and becomes a troublemaker (an oncogene). This troublemaker starts building too many illegal structures, leading to cancer.

For a long time, scientists have been developing a special kind of "trash can" called a PROTAC. Think of a PROTAC as a smart garbage truck. It has two hooks: one grabs the troublemaker worker, and the other grabs the city's official trash collector (the E3 ligase). Once connected, the trash collector drags the troublemaker to the incinerator (the proteasome) and burns it.

The big question this paper asks is: Does it matter how the troublemaker got so powerful in the first place?

The researchers found that there are two main ways a troublemaker gets too powerful, and the "garbage truck" handles them very differently.

---

Scenario A: The "Sticky" Worker (Protein Stabilization)

The Problem:
Imagine a worker who is naturally very short-lived; the city usually fires them after 10 minutes. But, a mutation happens that puts a super-strong "sticky tape" on their back. Now, the city's normal firing mechanism can't grab them. They stay on the job for hours, doing damage.

The Experiment:
The researchers created cells with these "sticky" troublemakers (mutations in the β-catenin protein). These cells had way more troublemakers than normal—up to 5 times as many.

The Result:
When they sent in the PROTAC garbage truck:

• Before the truck arrived: The "sticky" cells were full of troublemakers.
• After the truck arrived: The truck grabbed the sticky workers just as easily as the normal ones. It dragged them all to the incinerator.
• The Outcome: Even though the "sticky" cells started with more troublemakers, the garbage truck managed to clean them all the way down to the same low level as the normal cells.

The Lesson:
If the problem is just that the worker is "sticky" (hard to fire naturally), the PROTAC trash truck doesn't care. It can still clean the building completely. The starting amount didn't matter; the truck could get the level down to zero.

---

Scenario B: The "Factory" Worker (Transcriptional Upregulation)

The Problem:
Now, imagine a different scenario. The worker isn't sticky; they are easy to fire. However, someone has hacked the factory and turned the production line up to "Turbo Mode." The factory is now churning out 5 times more of these workers than usual. Even though the city fires them at the normal rate, the sheer volume of new workers arriving keeps the building full.

The Experiment:
The researchers used a switch (a chemical called Doxycycline) to turn up the production of the troublemaker protein in their cells.

The Result:
When they sent in the PROTAC garbage truck:

• Before the truck arrived: The building was full because the factory was running fast.
• After the truck arrived: The truck did its job and destroyed the workers. But, because the factory was still running at "Turbo Mode," new workers kept pouring in immediately.
• The Outcome: The garbage truck could only clean the building down to a higher level than before. It couldn't get the building empty because the supply line was too strong. The truck was fighting a losing battle against the production line.

The Lesson:
If the problem is that the factory is producing too much (high synthesis), the garbage truck hits a "ceiling." It can't clean the building as thoroughly because the new workers arrive faster than the truck can take them away.

---

Why This Matters for Medicine

The authors discovered that not all cancers are the same, even if they look similar under a microscope.

1. For "Sticky" Cancers: If a patient's cancer is caused by a mutation that makes the protein "sticky" (hard to degrade naturally), they are likely to respond very well to PROTAC drugs. The drug can wipe out the protein completely, regardless of how much was there to start with.
2. For "Factory" Cancers: If a patient's cancer is caused by the gene being copied too many times (amplification) or turned on too loudly (transcriptional upregulation), the PROTAC drug might struggle. The cancer cells might keep producing the protein faster than the drug can destroy it, leading to drug resistance.

The Takeaway Analogy

Think of a bathtub with a drain (the PROTAC) and a faucet (the protein production).

• Sticky Protein: The drain is clogged by a rubber duck (the mutation). You have a lot of water (protein) in the tub. If you pull the plug (PROTAC), the water drains out completely, even if the tub was full to the brim.
• Factory Protein: The drain is open, but someone has turned the faucet on full blast. Even if you pull the plug, the water level stays high because the faucet is filling the tub faster than the drain can empty it.

Conclusion:
To treat cancer effectively with these new drugs, doctors need to know why the bad protein is high in the first place. Is it because it's "sticky," or is it because the factory is running too fast? This distinction will determine if the "garbage truck" can save the day or if the cancer will fight back.

Technical Summary

1. Problem Statement

Proteolysis-Targeting Chimeras (PROTACs) are a class of drugs designed to degrade oncogenic proteins by recruiting E3 ubiquitin ligases to induce proteasomal degradation. While PROTACs are advancing in clinical trials, a critical gap exists in understanding how disease-associated changes in target protein homeostasis influence their efficacy.

Oncogenic proteins can be upregulated through two distinct mechanisms:

1. Stabilization: Mutations (e.g., in degron motifs) or loss of degradation machinery (e.g., APC loss) that extend protein half-life.
2. Overproduction: Gene amplification or transcriptional upregulation that increases synthesis rates.

It remains unclear whether these distinct mechanisms impose different constraints on PROTAC activity. Specifically, does a protein that is naturally long-lived (stabilized) respond differently to degradation than a protein that is simply being produced in high quantities (overproduced)?

2. Methodology

The authors developed an orthogonal experimental system using $\beta$-catenin (encoded by CTNNB1), a key oncoprotein in the Wnt signaling pathway, as a model substrate.

• Reporter System: They engineered a fusion protein: CTNNB1:dTAG:GFP.

  • dTAG (FKBP12$^{F36V}$): A small degron tag that allows rapid, ligand-induced degradation via recruitment of either CRL2$^{VHL}$ (using dTAGv1) or CRL4$^{CRBN}$ (using dTAG-13).
  • GFP: Enables sensitive, single-cell quantification of protein levels via flow cytometry.
  • Integration: Constructs were stably integrated into the genome of HEK293 cells (Flp-In and T-Rex systems) to ensure consistent copy numbers and promoter contexts.

• Experimental Conditions:

  1. Stabilization Model: They introduced specific missense mutations (S45F, T41A, S33F) into the native N-terminal degron of $\beta$-catenin. These mutations prevent phosphorylation by the destruction complex (GSK3$\beta$/CK1$\alpha$), thereby increasing protein half-life and steady-state levels.
  2. Overproduction Model: They utilized a T-Rex (Tetracycline-inducible) system to transcriptionally upregulate the expression of the WT or S45F mutant constructs using Doxycycline, thereby increasing the synthesis rate without altering intrinsic stability.

• Assays:

  • Dose-Response: Treatment with dTAGv1 or dTAG-13 to determine $DC_{50}$ (potency) and $D_{max}$ (maximum degradation).
  • Time-Course: Monitoring protein levels over 24 hours to observe steady-state convergence.
  • Validation: Confirmed that the fusion proteins retained transcriptional activity (measured via AXIN2 mRNA) and nuclear localization.
  • Clinical Correlation: Analyzed TCGA pan-cancer data to correlate CTNNB1 copy number variations with mRNA expression levels.

3. Key Contributions

• Decoupling Synthesis vs. Stability: The study provides the first empirical evidence distinguishing how PROTACs handle targets elevated via stabilization (reduced clearance) versus transcriptional induction (increased synthesis).
• Conceptual Framework: It establishes that the mechanism of oncogene activation fundamentally dictates the "ceiling" of achievable protein depletion by degraders.
• Quantitative Kinetics: The authors demonstrate that while stabilization raises the starting protein level, it does not alter the minimum level achievable by PROTACs, whereas increased synthesis shifts the entire steady-state equilibrium upward.

4. Key Results

A. Effect of Stabilizing Mutations (Reduced Clearance)

• Baseline Increase: Mutations in the native degron (S45F, T41A, S33F) increased steady-state $\beta$-catenin levels by 3-fold to 5-fold compared to Wild Type (WT).
• PROTAC Efficacy: Despite the higher starting levels, PROTAC treatment (dTAGv1/dTAG-13) drove absolute protein levels to the same minimum baseline for both WT and mutants after 24 hours.
• Fractional vs. Absolute: When analyzed as fractional reduction (percentage of remaining protein), mutants appeared less sensitive. However, this was an artifact of the higher baseline; in absolute terms, the PROTACs were equally effective at clearing the protein regardless of the mutation.
• Conclusion: Stabilizing mutations do not confer resistance to the depth of degradation; they only raise the pre-treatment set point.

B. Effect of Transcriptional Induction (Increased Synthesis)

• Baseline Increase: Doxycycline induction increased protein expression by ~2.8-fold (WT) and ~5.2-fold (S45F).
• PROTAC Efficacy: Unlike stabilization, transcriptional upregulation resulted in elevated absolute protein levels even after 24 hours of PROTAC treatment.
• The "Synthesis Ceiling": The fractional degradation maximum ($D_{max}$) remained unchanged, but the absolute steady-state level shifted upward. The PROTAC could not deplete the protein to the same low baseline seen in non-induced cells because the high synthesis rate counteracted the degradation rate.
• Conclusion: High synthesis rates impose a hard limit on the depth of depletion achievable by PROTACs.

C. Clinical Relevance (TCGA Data)

• Analysis of Wnt-active tumors (LIHC, UCEC, COAD, STAD) showed that CTNNB1 copy number gains correlate with increased mRNA levels.
• While CTNNB1 amplification is rare, the authors note that other common degrader targets (e.g., cMYC, EGFR, nMYC) frequently undergo gene amplification, suggesting this "synthesis ceiling" effect is a widespread clinical concern.

5. Significance and Implications

• Drug Resistance Prediction: Tumors driven by gene amplification (high synthesis) may be inherently resistant to deep depletion by PROTACs, as the drug cannot overcome the high flux of new protein synthesis. Conversely, tumors driven by stabilizing mutations (e.g., CTNNB1 exon 3 mutations, APC loss) should remain highly responsive to degraders, despite high baseline protein levels.
• Preclinical Modeling: Current models often rely on transient transfection (high copy number) or specific cell lines. This study suggests that models must account for the proteostatic state (synthesis rate vs. degradation rate) of the target to accurately predict clinical efficacy.
• Personalized Medicine: Therapeutic strategies should be tailored based on the genetic mechanism of oncogene activation. Patients with amplification-driven tumors might require combination therapies (e.g., degraders + synthesis inhibitors), while those with stabilization-driven tumors may respond well to degraders alone.
• Mathematical Validation: The results align with theoretical kinetic models (Bartlett & Gilbert, Vetma et al.) suggesting that induced degradation kinetics dominate endogenous turnover for stable proteins, but synthesis rates become the limiting factor when production is artificially elevated.

In summary, this paper clarifies that how an oncogene is activated determines how well a PROTAC can degrade it. Stabilization raises the floor but not the ceiling of degradation, whereas overproduction raises both, potentially limiting therapeutic efficacy.